The medication is an investigational once-daily oral GLP-1 receptor agonist designed to help people lose weight and improve blood sugar control
What they did: Multiple preclinical models (mice, rats) evaluated the combination AOD-9604 + GLP-1 agonist (Semaglutide or Liraglutide)
Studies suggest that all three peptides appear synergistic when combined as a blend, potentially providing unique peptide effects
Any direct protective effect on ocular tissues, however, remains unproven
When accompanied by metabolic disorders, such as IR and dyslipidaemia, it can lead to hyperlipidaemia, hypertension, metabolic syndrome and diabetes
These small moments of recovery help lower cortisol levels and support the hormonal systems involved in appetite and energy regulation